TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: BIOCON · data 2026-11-03
Biocon Limited
In plain words
Price: 20.7% below its 52-week high of ₹447.15.
Delivery: 48.9% of traded shares were kept for delivery over the last 10 sessions, against 51.5% over the last 60.
Latest results: a net profit of ₹141 cr for the quarter ended Jun 2026 (+349.4% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹17,321 cr |
| Net profit (last 12 months) | ₹495 cr |
| Sales growth, 3 years (yearly) | 15.2% |
| Profit growth, 3 years (yearly) | -5.9% |
At a glance
Promoters 44.7% (-9.8 pts in a year), pledged 0.0%, institutions 37.9%.
P/E 105.5, P/B 1.6, dividend yield 0.1%. Price relative to earnings and book value (low is cheaper, not better).
ROE 1.4%, ROCE 3.5%, operating margin 8.6%: how much profit it earns on the money it uses.
Debt/equity 0.45, Profit growth -5.9% and sales growth 15.2% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Low return on equity (1.4%).
- Profit fell 5.9% a year over 3 years.
- Promoters cut their holding by 9.8 points in a year.
- Expensive on earnings (P/E 105.5).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
BIOCON Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹4,336 crore, up 10% YoY and down 4% QoQ.
Net profit was ₹141.1 crore, up 349.4% YoY and up 12.1% QoQ.
Operating margin was 19.5% (19% a year ago).
EPS was ₹0.87, up 357.9% YoY and up 10.1% QoQ.
BIOCON के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹4,336 करोड़; पिछले साल की तुलना में 10% की बढ़त, पिछली तिमाही की तुलना में 4% की गिरावट।
शुद्ध मुनाफ़ा: ₹141.1 करोड़; पिछले साल की तुलना में 349.4% की बढ़त, पिछली तिमाही की तुलना में 12.1% की बढ़त।
ऑपरेटिंग मार्जिन: 19.5% (एक साल पहले 19%)।
EPS: ₹0.87; पिछले साल की तुलना में 357.9% की बढ़त, पिछली तिमाही की तुलना में 10.1% की बढ़त।
BIOCONના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹4,336 કરોડ; ગયા વર્ષની સરખામણીએ 10% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 4% ઘટાડો.
ચોખ્ખો નફો: ₹141.1 કરોડ; ગયા વર્ષની સરખામણીએ 349.4% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 12.1% વધારો.
ઓપરેટિંગ માર્જિન: 19.5% (એક વર્ષ પહેલાં 19%).
EPS: ₹0.87; ગયા વર્ષની સરખામણીએ 357.9% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 10.1% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
22/100 · Weak over the last ~60 sessions, data 2026-11-02
- Delivery vs usual 4/30: Delivery 53.3% over the last 20 sessions vs 49.8% in the 40 before (1.07x); shares delivered per day 0.93x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 13/15: 30 schemes hold it, about ₹5,988 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 5 Aug 26Results Q1 FY27 results: net profit ₹141.1 cr +3.5% next session
- 3 Jul 26Dividend Dividend ₹0.5 (ex-date) +1.4% next session
- 11 Nov 25Results Q2 FY26 results: net profit ₹84.5 cr +6.2% next session
- 4 Jul 25Dividend Dividend ₹0.5 (ex-date) -0.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹4,336 cr | ₹141 cr | +349.4% | 19.5% | 0.87 |
| Mar 2026 | ₹4,517 cr | ₹126 cr | -63.5% | 22.6% | 0.79 |
| Dec 2025 | ₹4,173 cr | ₹144 cr | +472.9% | 20.0% | 1.08 |
| Sept 2025 | ₹4,296 cr | ₹85 cr | — | 19.4% | 0.66 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 44.68% | 44.68% | 44.91% | 54.45% |
| Foreign institutions (FII) | 8.64% | 8.14% | 7.52% | 7.39% |
| Domestic institutions (DII) | 29.30% | 23.38% | 24.07% | 21.71% |
| Mutual funds | 22.08% | 15.47% | 16.53% | 13.75% |
| Retail investors | 5.88% | 5.84% | 5.77% | 7.16% |
| Number of shareholders | 3,93,051 | 3,92,833 | 3,86,593 | 3,94,279 |
Common questions
What was Biocon Limited's latest quarterly profit?
Biocon Limited reported a net profit of ₹141 cr for the quarter ended Jun 2026 (+349.4% on the same quarter a year earlier), on revenue of ₹4,336 cr.
How much do promoters hold in Biocon Limited?
Promoters held 44.68% of Biocon Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Biocon Limited debt-free?
Its latest reported debt-to-equity ratio is 0.45.
What is Biocon Limited's P/E ratio?
About 105.5, based on the last 12 months' earnings and a price of ₹354.7 (data 2026-11-03).
What is the 52-week high and low of Biocon Limited?
The 52-week high is ₹447.15 and the 52-week low is ₹318.4.
Mutual funds holding Biocon Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 30 schemes holding about ₹5,988 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Contra Fund | SBI Mutual Fund | 3.29% | ₹1,483 cr |
| SBI Large and Midcap Fund | SBI Mutual Fund | 2.20% | ₹891 cr |
| SBI Midcap Fund | SBI Mutual Fund | 2.48% | ₹577 cr |
| SBI Balanced Advantage Fund | SBI Mutual Fund | 1.19% | ₹483 cr |
| SBI MultiCap Fund | SBI Mutual Fund | 1.74% | ₹408 cr |
| SBI Multi Asset Allocation Fund | SBI Mutual Fund | 1.39% | ₹293 cr |
| SBI Flexicap Fund | SBI Mutual Fund | 1.17% | ₹259 cr |
| ADITYA BIRLA SUN LIFE FOCUSED FUND | Aditya Birla Sun Life Mutual Fund | 3.03% | ₹228 cr |
| SBI MNC Fund | SBI Mutual Fund | 2.61% | ₹167 cr |
| SBI ELSS Tax Saver Fund | SBI Mutual Fund | 0.50% | ₹150 cr |
| SBI Dividend Yield Fund | SBI Mutual Fund | 1.86% | ₹150 cr |
| SBI Conservative Hybrid Fund | SBI Mutual Fund | 1.39% | ₹141 cr |
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 2.37% | ₹139 cr |
| Nippon India Focused Fund | Nippon India Mutual Fund | 1.57% | ₹127 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 1.01% | ₹93 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Biocon Limited | ₹354.7 | ₹57,310 cr | 105.5 | 1.6 | 1.4% | 3.5% | 0.45 | -6.2% |
| Glenmark Pharmaceuticals Limited | ₹2,382 | ₹65,137 cr | 37.4 | — | 14.1% | 29.2% | 0.06 | +26.5% |
| Alkem Laboratories Ltd. | ₹5,155 | ₹61,277 cr | 28.6 | — | 17.8% | 17.8% | 0.15 | -6.7% |
| Abbott India Limited | ₹25,820 | ₹54,384 cr | 34 | — | 34.5% | 39.1% | 0.04 | -12.8% |
| Gland Pharma Ltd. | ₹3,066.6 | ₹51,112 cr | 44.8 | — | 10.5% | 12% | 0.03 | +59.8% |
| IPCA Laboratories Limited | ₹1,949.9 | ₹48,898 cr | 37.8 | — | 15.2% | 16.3% | 0.1 | +50.5% |
Compare BIOCON with GLENMARK in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open BIOCON in TickerKhoj →